Defensive financial decisions support for retailers in Greek pharmaceutical industry

被引:4
|
作者
Marinakos, Georgios [1 ]
Daskalaki, Sophia [1 ]
Ntrinias, Theodoros [2 ]
机构
[1] Univ Patras, Dept Engn Sci, Patras, Greece
[2] Univ Salford Business Sch, Salford, Lancs, England
关键词
Financial performance monitoring; Profitability and liquidity; Cash flow management; Decision support systems; Neural networks;
D O I
10.1007/s10100-013-0325-4
中图分类号
C93 [管理学]; O22 [运筹学];
学科分类号
070105 ; 12 ; 1201 ; 1202 ; 120202 ;
摘要
In this paper, we present a decisions support solution designed for Greek pharmacies comprising a cash flow management system for early warning of financial distress and a financial advisor based on a neural network. The cash flow monitoring system integrates accounting elements with real time transactions and a predictive linear regression model while the decision support module is developed with the help of a neural network. For any given business unit the system associates accounting entries with information about credit times to reflect the precise instants of cash flows and using inflows/outflows equations monthly, eventually build its liquidity curve and cash flow balance over time. Alongside, a linear regression module is introduced to estimate future cash reserves based on past profitability ratios. Lastly, combining the power of artificial neural networks with expertise in this sector of pharmaceutical business, the financial decision support tool focuses on the retailers that face financial difficulties and suggests alternative solutions for escaping from distress and insolvency. The model has an ambitious and useful purpose, to inform and consult the owners of the business units and other members of the pharmaceutical chain, thus reduce financial risk for the chain.
引用
收藏
页码:525 / 551
页数:27
相关论文
共 50 条
  • [1] Defensive financial decisions support for retailers in Greek pharmaceutical industry
    Georgios Marinakos
    Sophia Daskalaki
    Theodoros Ntrinias
    [J]. Central European Journal of Operations Research, 2014, 22 : 525 - 551
  • [2] Pharmaceutical Industry Financial Support for Medical Education: Benefit, or Undue Influence?
    Brody, Howard
    [J]. JOURNAL OF LAW MEDICINE & ETHICS, 2009, 37 (03): : 451 - +
  • [3] A FINANCIAL PERSPECTIVE ON THE PHARMACEUTICAL INDUSTRY
    Kahraman, Yunus Emre
    Caliskan, Yilmaz
    [J]. PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, (01): : 23 - 31
  • [4] Pharmaceutical industry financial performance
    Goodman, Michael
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (12) : 927 - 928
  • [5] Pharmaceutical industry financial performance
    Michael Goodman
    [J]. Nature Reviews Drug Discovery, 2009, 8 : 927 - 928
  • [6] THE ECONOMIC FOOTPRINT OF THE GREEK PHARMACEUTICAL INDUSTRY
    Tserkezis, E.
    Paratsiokas, N.
    Tsakanikas, A.
    Athanasiadis, A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A580 - A581
  • [7] Innovation and merger decisions in the pharmaceutical industry
    Morgan, EJ
    [J]. REVIEW OF INDUSTRIAL ORGANIZATION, 2001, 19 (02) : 181 - 197
  • [8] Entry decisions in the generic pharmaceutical industry
    Morton, FMS
    [J]. RAND JOURNAL OF ECONOMICS, 1999, 30 (03): : 421 - 440
  • [9] Innovation and Merger Decisions in the Pharmaceutical Industry
    Eleanor J. Morgan
    [J]. Review of Industrial Organization, 2001, 19 : 181 - 197
  • [10] Financial risk of the Biotech Industry versus the Pharmaceutical Industry
    Joseph Golec
    John A. Vernon
    [J]. Applied Health Economics and Health Policy, 2009, 7 (3) : 155 - 165